Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

64.17 +56.44 (+730.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
What's going on in today's after hours session
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
A Look at MiNK Therapeutics's Upcoming Earnings Report
Via Benzinga
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with... 
Via Benzinga
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
Via Benzinga
Topics Stocks
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy
“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said. 
Via Stocktwits
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors 
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings 
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
Via Benzinga
Earnings Scheduled For March 18, 2025
Via Benzinga
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers 
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
The market is filled with gapping stocks in Tuesday's session.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer 
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.